Q2 2021 Results - Reimagining Medicine

Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations BeovuⓇ - Anti-VEGF Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04005352 TALON (CRTH258A2303) Neovascular Age-related Macular Degeneration (nAMD) Phase 3B Average change in Best-corrected visual acuity Distribution of the last interval with no disease activity (in a Treat-to-Control regimen) Arm 1: Brolucizumab 6 mg intravitreal injection Arm 2: Aflibercept 2 mg intravitreal injection Patients with Neovascular Age-related Macular Degeneration (nAMD) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment Target Patients Read-out Milesstone(s) 2022 Publication TBD NCT04047472 HOBBY (CRTH258A2307) Macular degeneration Phase 3 494 Change from baseline in best-corrected visual acuity (BCVA) at week 48 Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Chinese patients with neovascular age-related macular degeneration 2024 TBD 121 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation